|
|
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) |
|
Overall company Market Share Q1 2025 |
*Market share is calculated based on total revenue.
News about Verrica Pharmaceuticals Inc Contracts |
October 2, 2024
In an eye-catching move aimed at recalibrating its strategic trajectory, Verrica Pharmaceuticals Inc. has recently announced a comprehensive restructuring of its commercial organization, a decision necessitated by a sobering year amidst severe market challenges. As the company grapples with a staggering 75.18% decline in its share price year to date significantly outpacing the broader market s 20.99% rise this realignment appears both prudent and imperative for long-term sustainability.The restructuring initiative is designed to substantially reduce the company?s cost structure, thereby enhancing operational efficiencies across sales and marketing. By streamlining its commercial infrastructure, Verrica seeks...
|
August 14, 2024
Positive Advances in Basal Cell Carcinoma Treatment: Verrica Pharmaceuticals VP-315 Shows Promising Results In an inspiring stride towards combating Basal Cell Carcinoma (BCC), Verrica Pharmaceuticals recently unveiled positive preliminary topline results from Part 2 of their Phase 2 clinical study of VP-315. This investigational oncolytic peptide-based immunotherapy, aimed at treating patients with BCC, has shown significant promise in its early trials.Basal Cell Carcinoma is the most common form of skin cancer, often resulting in disfiguring lesions and requiring invasive treatments. The development of innovative, non-surgical treatments is crucial for improving patient outcomes and quality of life. Verri...
|
July 1, 2024
Verrica Pharmaceuticals, a dermatology therapeutics company, has recently announced a litigation settlement with Dormer Laboratories, Inc. The settlement has led to Dormer Labs discontinuing the sale of all cantharidin-containing products into the United States. Cantharidin is a substance derived from blister beetles and is commonly used in the treatment of skin conditions.The settlement comes as a result of a dispute between Verrica Pharmaceuticals and Dormer Laboratories, Inc. regarding the sale and distribution of cantharidin-containing products in the United States. Through their legal proceedings, Verrica Pharmaceuticals has successfully reached an agreement with Dormer Labs, leading to the discontinuat...
|
May 27, 2024
In recent news, Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) finds itself under the scrutiny of Bragar Eagel and Squire, P.C., a well-respected shareholder rights law firm. The firm has initiated an investigation after the filing of a class action complaint against Verrica, raising questions about the company s management practices and possible breaches of fiduciary duties by its board of directors. This development has significant implications for long-term stockholders, as potential claims against the pharmaceutical company come into focus.The Allegations:Bragar Eagel and Squire s investigation centers around a class period ranging from May 28, 2021, to May 24, 2022. The firm aims to determine whether Verr...
|
May 15, 2024
Verrica Pharmaceuticals Inc. has announced a significant amendment to its collaboration and license agreement with Japan-based Torii Pharmaceutical Co. Ltd. This strategic modification aims to fund and facilitate a global pivotal Phase 3 clinical trial to study YCANTH for the treatment of common warts. The jointly conducted trial is expected to commence in the first half of 2025. BackgroundCommon warts, caused by the human papillomavirus (HPV), represent a widespread dermatological condition affecting millions worldwide. Despite the prevalence, the market remains underserved with effective and safe treatment options being limited. Verrica Pharmaceuticals has been pioneering the development of YCANTH (canthar...
|
March 26, 2024
Verrica Pharmaceuticals, a renowned pharmaceutical company, has recently announced that its product YCANTH has received the prestigious New Chemical Entity (NCE) status from the U.S. Food and Drug Administration (FDA). This regulatory milestone grants Verrica a minimum of five years of market exclusivity, paving the way for potential commercial success and furthering their mission to address unmet medical needs. This article aims to outline the facts surrounding this groundbreaking development and shed light on the significance of this achievement for Verrica Pharmaceuticals and its investors.Facts:1. YCANTH, a pharmaceutical product developed by Verrica Pharmaceuticals, has received New Chemical Entity (NCE...
|
January 29, 2024
Verrica Pharmaceuticals, a leading dermatology therapeutics company, has recently received a significant milestone in its quest to provide medical interventions for skin diseases. The Centers for Medicare and Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Verrica s groundbreaking medication, YCANTH. This marks a crucial step forward in treating molluscum contagiosum, a common skin condition affecting millions worldwide.Promoting Access to Innovative TreatmentMolluscum contagiosum is a viral skin infection characterized by small, raised, and painless lesions on the skin. It most commonly affects children, but can also impact adults, particularly those with weakened immune systems. Until now...
|
Publicly Traded Peers of Verrica Pharmaceuticals Inc
Amgen Inc
Share Performance
-2.92%
30 Days
|
Amgen Inc
Profile
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
More about Amgen Inc 's Market Share
|
Aclaris Therapeutics Inc
Share Performance
-49.19%
This Year
|
Aclaris Therapeutics Inc
Profile
Aclaris Therapeutics Inc is a company that focuses on developing and commercializing innovative therapies to address significant unmet needs in dermatology and immunology. Their business model involves researching and developing treatments for various skin and hair conditions, obtaining regulatory approvals, and marketing these therapies to healthcare professionals and patients.
More about Aclaris Therapeutics Inc 's Market Share
|
Novavax inc
Share Performance
-53.23%
One Year
|
Novavax inc
Profile
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
More about Novavax inc 's Market Share
|
Optinose Inc
Share Performance
+4.80%
30 Days
|
Optinose Inc
Profile
Optinose Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies delivered through its proprietary device called Optinose Exhalation Delivery System. They generate revenue by licensing and selling their treatment products for conditions like nasal polyps and migraines.
More about Optinose Inc 's Market Share
|
Dermata Therapeutics Inc
Share Performance
-10.36%
Over The Past 5 Days
|
Dermata Therapeutics Inc
Profile
Dermata Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing dermatology and skin care products, focusing on innovative treatments for various skin conditions.
More about Dermata Therapeutics Inc 's Market Share
|
Savara Inc
Share Performance
-30.39%
One Year
|
Savara Inc
Profile
Savara Inc operates as a biopharmaceutical company that focuses on developing and commercializing therapies for rare respiratory diseases. Their business model revolves around conducting research and development activities to identify and develop novel treatments, obtaining regulatory approvals for their products, and subsequently marketing and selling these therapies to patients and healthcare providers. By targeting unmet medical needs in the respiratory field, Savara aims to improve the lives of individuals suffering from these rare diseases.
More about Savara Inc 's Market Share
|
Bristol myers Squibb Company
Share Performance
-3.78%
30 Days
|
Bristol myers Squibb Company
Profile
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
More about Bristol myers Squibb Company's Market Share
|
Abbvie Inc
Share Performance
-1.32%
Over The Past 5 Days
|
Abbvie Inc
Profile
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
More about Abbvie Inc 's Market Share
|
Eli Lilly And Company
Share Performance
-8.27%
This Year
|
Eli Lilly And Company
Profile
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
More about Eli Lilly And Company's Market Share
|
Novartis Ag
Share Performance
+1.42%
30 Days
|
Novartis Ag
Profile
Novartis AG's business model is centered around the development, manufacturing, and marketing of innovative pharmaceutical products.
More about Novartis Ag's Market Share
|
Regeneron Pharmaceuticals Inc
Share Performance
-40.27%
One Year
|
Regeneron Pharmaceuticals Inc
Profile
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
More about Regeneron Pharmaceuticals Inc 's Market Share
|
Spectrum Pharmaceuticals Inc
Share Performance
+169.28%
This Year
|
Spectrum Pharmaceuticals Inc
Profile
Spectrum Pharmaceuticals Inc operates under a business model focused on the development, acquisition, and commercialization of oncology and hematology drugs. The company aims to bring innovative therapies to patients by leveraging its expertise in drug development, manufacturing capabilities, and commercial infrastructure. Spectrum focuses on both the internal development of new drugs as well as strategic collaborations and licensing agreements with other pharmaceutical companies.
More about Spectrum Pharmaceuticals Inc 's Market Share
|
Ligand Pharmaceuticals Incorporated
Share Performance
-15.80%
This Quarter
|
Ligand Pharmaceuticals Incorporated
Profile
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
More about Ligand Pharmaceuticals Incorporated's Market Share
|
Tg Therapeutics Inc
Share Performance
-14.22%
30 Days
|
Tg Therapeutics Inc
Profile
TG Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for patients with hematological malignancies and autoimmune diseases.
More about Tg Therapeutics Inc 's Market Share
|
Apexigen Inc
Share Performance
-92.87%
One Year
|
Apexigen Inc
Profile
Apexigen Inc's business model revolves around developing and commercializing novel antibody-based therapeutics. They focus on discovering and optimizing antibody drugs through their proprietary technology platforms. By partnering with pharmaceutical companies or utilizing their own resources, they aim to provide innovative solutions for treating various diseases and improving patients' lives.
More about Apexigen Inc 's Market Share
|
Deciphera Pharmaceuticals Inc
Share Performance
+82.52%
One Year
|
Deciphera Pharmaceuticals Inc
Profile
Deciphera Pharmaceuticals Inc's business model revolves around the research, development, and commercialization of precision medicines for the treatment of cancer and other serious diseases.
More about Deciphera Pharmaceuticals Inc 's Market Share
|
Affimed N v
Share Performance
0.00%
This Quarter
|
Affimed N v
Profile
Affimed N is a biopharmaceutical company that operates through a partnership-based business model, collaborating with leaders in the healthcare industry and utilizing its proprietary technology platform to develop novel cancer immunotherapies. By leveraging these collaborations and its innovative platform, Affimed N aims to advance the development of effective treatments for cancer.
More about Affimed N v 's Market Share
|
Corbus Pharmaceuticals Holdings Inc
Share Performance
-4.64%
Over The Past 5 Days
|
Corbus Pharmaceuticals Holdings Inc
Profile
Corbus Pharmaceuticals Holdings Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for inflammatory and fibrotic diseases. Their business model revolves around conducting research and clinical trials to identify potential drug candidates, obtaining regulatory approvals, and subsequently commercializing these drugs to generate revenue. They aim to address unmet medical needs by creating and marketing novel treatments for diseases such as systemic sclerosis, cystic fibrosis, and other inflammatory conditions.
More about Corbus Pharmaceuticals Holdings Inc 's Market Share
|
Nextcure Inc
Share Performance
+12.84%
Over The Past 5 Days
|
Nextcure Inc
Profile
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
More about Nextcure Inc 's Market Share
|
Enanta Pharmaceuticals Inc
Share Performance
+3.94%
This Year
|
Enanta Pharmaceuticals Inc
Profile
Enanta Pharmaceuticals Inc's business model focuses on the research, development, and commercialization of innovative small molecule drugs targeting viral infections and liver diseases.
More about Enanta Pharmaceuticals Inc's Market Share
|
Bolt Biotherapeutics Inc
Share Performance
-34.02%
This Quarter
|
Bolt Biotherapeutics Inc
Profile
Bolt Biotherapeutics Inc's business model focuses on developing novel immunotherapies for the treatment of cancer.
More about Bolt Biotherapeutics Inc 's Market Share
|
Galecto Inc
Share Performance
-81.01%
One Year
|
Galecto Inc
Profile
Galecto Inc operates on a business model that focuses on developing novel therapeutics based on galectin inhibitors, targeting fibrosis and inflammation-related diseases. The company aims to bring these innovative drugs to market by leveraging their expertise in drug discovery and development, while forming strategic partnerships and collaborations within the pharmaceutical industry.
More about Galecto Inc 's Market Share
|
Gt Biopharma Inc
Share Performance
+34.42%
This Quarter
|
Gt Biopharma Inc
Profile
Gt Biopharma Inc's business model revolves around developing innovative immunotherapies for the treatment of various cancers. The company focuses on harnessing the power of the immune system to target and eliminate cancer cells through its proprietary technology platform. Gt Biopharma Inc aims to advance its therapies through clinical trials and ultimately commercialize them for the benefit of patients worldwide.
More about Gt Biopharma Inc 's Market Share
|
Aravive Inc
Share Performance
-68.96%
This Year
|
Aravive Inc
Profile
Aravive Inc operates on a business model that focuses on developing and commercializing innovative therapies to treat life-threatening diseases by targeting key signaling pathways.
More about Aravive Inc 's Market Share
|
Novan Inc
Share Performance
-92.92%
This Quarter
|
Novan Inc
Profile
Novan Inc is a biotechnology company that operates on a dermatology-focused business model. They develop and commercialize innovative therapies that address unmet medical needs in dermatology by utilizing their proprietary nitric oxide technology platform. Novan Inc primarily focuses on developing topical treatments for a range of skin conditions such as acne, atopic dermatitis, and fungal infections.
More about Novan Inc 's Market Share
|
Skinvisible Inc
Share Performance
-59.90%
This Quarter
|
Skinvisible Inc
Profile
Skinvisible Inc's business model revolves around the development, licensing, and sale of innovative and patented skincare technologies and formulations for use in various consumer and pharmaceutical applications.
More about Skinvisible Inc 's Market Share
|
Inhibitor Therapeutics Inc
Share Performance
0.00%
30 Days
|
Inhibitor Therapeutics Inc
Profile
Inhibitor Therapeutics Inc's business model focuses on developing and commercializing innovative inhibitors for targeted therapies.
More about Inhibitor Therapeutics Inc 's Market Share
|
Dmk Pharmaceuticals Corporation
Share Performance
-65.61%
This Year
|
Dmk Pharmaceuticals Corporation
Profile
DMK Pharmaceuticals Corporation has a business model focused on the development, manufacturing, and distribution of pharmaceutical products.
More about Dmk Pharmaceuticals Corporation's Market Share
|
Rapt Therapeutics Inc
Share Performance
-70.57%
One Year
|
Rapt Therapeutics Inc
Profile
Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.
More about Rapt Therapeutics Inc 's Market Share
|
Erasca Inc
Share Performance
-12.86%
30 Days
|
Erasca Inc
Profile
Erasca Inc is a biotechnology company that focuses on discovering and developing innovative therapies for cancer. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to identify and advance multiple drug candidates simultaneously. By collaborating with academic institutions and biopharmaceutical partners, Erasca aims to accelerate the development of cancer treatments to improve patient outcomes.
More about Erasca Inc 's Market Share
|
Verastem Inc
Share Performance
+28.04%
This Year
|
Verastem Inc
Profile
Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.
More about Verastem Inc 's Market Share
|
Zai Lab Limited
Share Performance
-7.28%
This Quarter
|
Zai Lab Limited
Profile
Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.
More about Zai Lab Limited's Market Share
|
Merck and Co Inc
Share Performance
-2.83%
30 Days
|
Merck and Co Inc
Profile
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
More about Merck and Co Inc 's Market Share
|
Tonix Pharmaceuticals Holding Corp
Share Performance
+68.30%
30 Days
|
Tonix Pharmaceuticals Holding Corp
Profile
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.
More about Tonix Pharmaceuticals Holding Corp 's Market Share
|
Karyopharm Therapeutics Inc
Share Performance
-23.12%
30 Days
|
Karyopharm Therapeutics Inc
Profile
Karyopharm Therapeutics Inc's business model revolves around developing and commercializing novel therapeutic products to treat various types of cancers and other diseases.
More about Karyopharm Therapeutics Inc 's Market Share
|
Arcutis Biotherapeutics Inc
Share Performance
-3.98%
This Year
|
Arcutis Biotherapeutics Inc
Profile
Arcutis Biotherapeutics Inc's business model revolves around developing and commercializing innovative treatments for various dermatological conditions.
More about Arcutis Biotherapeutics Inc 's Market Share
|
Nucana Plc
Share Performance
-94.15%
30 Days
|
Nucana Plc
Profile
Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.
More about Nucana Plc's Market Share
|
Zynerba Pharmaceuticals Inc
Share Performance
-2.26%
30 Days
|
Zynerba Pharmaceuticals Inc
Profile
Zynerba Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative transdermal cannabinoid therapies. They utilize their proprietary technology to deliver cannabinoid molecules through the skin, providing targeted treatment for various medical conditions. Zynerba Pharmaceuticals aims to provide effective, safe, and convenient therapeutic options for patients in need.
More about Zynerba Pharmaceuticals Inc 's Market Share
|
Veru Inc
Share Performance
-9.22%
30 Days
|
Veru Inc
Profile
Veru Inc operates as a pharmaceutical company primarily focused on developing and commercializing medicines for men's and women's health. With a combination of in-house research and partnerships, Veru Inc aims to address unmet medical needs by providing innovative therapies and products. Their business model encompasses both the development of new pharmaceuticals and the marketing and distribution of their existing products in the healthcare market.
More about Veru Inc 's Market Share
|
Moleculin Biotech Inc
Share Performance
-4.28%
Over The Past 5 Days
|
Moleculin Biotech Inc
Profile
Moleculin Biotech Inc is a biopharmaceutical company that develops innovative cancer therapies by targeting key enzymes and signaling pathways involved in the progression of tumors. Their business model revolves around conducting preclinical and clinical trials to advance their drug candidates, with a focus on maximizing therapeutic impact and commercial potential.
More about Moleculin Biotech Inc 's Market Share
|
Ampio Pharmaceuticals inc
Share Performance
0.00%
One Year
|
Ampio Pharmaceuticals inc
Profile
Ampio Pharmaceuticals Inc is a biopharmaceutical company primarily focused on the development of therapies for debilitating diseases. Their business model revolves around identifying unmet medical needs and developing innovative drug candidates to address these needs. They aim to create value through successful clinical development and commercialization of their products, ultimately benefiting patients and generating revenue for the company.
More about Ampio Pharmaceuticals inc 's Market Share
|
Biofrontera Inc
Share Performance
-39.07%
One Year
|
Biofrontera Inc
Profile
Biofrontera Inc is a pharmaceutical company that specializes in developing and commercializing dermatological treatments for various skin conditions. Their business model revolves around research and development to create innovative products, obtaining regulatory approvals, and marketing and selling their products globally through direct sales teams and distribution partnerships. They aim to provide patients with effective and safe dermatological treatments while generating revenues through product sales.
More about Biofrontera Inc 's Market Share
|
Palatin Technologies Inc
Share Performance
-89.13%
This Quarter
|
Palatin Technologies Inc
Profile
Palatin Technologies Inc has a business model focused on developing and commercializing innovative medicines in the field of reproductive healthcare and sexual dysfunction. The company's revenue streams primarily come from partnerships, licensing agreements, and product sales.
More about Palatin Technologies Inc 's Market Share
|
Cyclacel Pharmaceuticals Inc
Share Performance
-75.57%
This Year
|
Cyclacel Pharmaceuticals Inc
Profile
Cyclacel Pharmaceuticals Inc is a biopharmaceutical company primarily focused on the development and commercialization of small molecule drugs that target various types of cancer. They utilize a collaborative approach in their research and development efforts, working closely with academic institutions and other industry partners. Cyclacel's business model revolves around advancing their innovative oncology pipeline, conducting clinical trials to assess the efficacy of their products, and ultimately bringing potential therapies to market for the treatment of cancer patients.
More about Cyclacel Pharmaceuticals Inc 's Market Share
|
Landos Biopharma Inc
Share Performance
+3.38%
30 Days
|
Landos Biopharma Inc
Profile
Lando's Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing innovative biopharmaceutical products to address unmet medical needs. Their business model revolves around conducting research and development, obtaining regulatory approvals, and marketing and selling their products in the global pharmaceutical market.
More about Landos Biopharma Inc 's Market Share
|
Pliant Therapeutics Inc
Share Performance
-90.29%
This Year
|
Pliant Therapeutics Inc
Profile
Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.
More about Pliant Therapeutics Inc 's Market Share
|
Protagonist Therapeutics inc
Share Performance
+17.14%
This Year
|
Protagonist Therapeutics inc
Profile
Protagonist Therapeutics Inc's business model focuses on the development and commercialization of novel peptide-based therapeutics.
More about Protagonist Therapeutics inc 's Market Share
|
Rhythm Pharmaceuticals inc
Share Performance
+1.81%
Over The Past 5 Days
|
Rhythm Pharmaceuticals inc
Profile
Rhythm Pharmaceuticals Inc's business model focuses on developing and commercializing therapies for rare genetic disorders that result in unmet medical needs.
More about Rhythm Pharmaceuticals inc 's Market Share
|
Adagene Inc
Share Performance
-11.65%
This Quarter
|
Adagene Inc
Profile
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
More about Adagene Inc 's Market Share
|
Nektar Therapeutics
Share Performance
-31.86%
This Year
|
Nektar Therapeutics
Profile
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
More about Nektar Therapeutics's Market Share
|
Mannkind Corporation
Share Performance
-7.83%
Over The Past 5 Days
|
Mannkind Corporation
Profile
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
More about Mannkind Corporation's Market Share
|
Puma Biotechnology Inc
Share Performance
-9.64%
Over The Past 5 Days
|
Puma Biotechnology Inc
Profile
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
More about Puma Biotechnology Inc 's Market Share
|
Myovant Sciences Ltd
Share Performance
+0.71%
This Quarter
|
Myovant Sciences Ltd
Profile
Myovant Sciences Ltd operates under a biopharmaceutical business model primarily focused on the development and commercialization of therapies for women's health and prostate cancer. The company aims to leverage its expertise in clinical research, regulatory affairs, and manufacturing to bring innovative treatments to market and improve patients' lives. Myovant Sciences employs a combination of in-house research and development along with collaboration with strategic partners to advance its pipeline of product candidates.
More about Myovant Sciences Ltd 's Market Share
|
Medicinova Inc
Share Performance
-33.80%
This Year
|
Medicinova Inc
Profile
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
More about Medicinova Inc 's Market Share
|
Matinas Biopharma Holdings Inc
Share Performance
-90.22%
One Year
|
Matinas Biopharma Holdings Inc
Profile
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
More about Matinas Biopharma Holdings Inc 's Market Share
|
Therapeuticsmd Inc
Share Performance
+11.54%
This Quarter
|
Therapeuticsmd Inc
Profile
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
More about Therapeuticsmd Inc's Market Share
|
Opko Health Inc
Share Performance
-7.35%
One Year
|
Opko Health Inc
Profile
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
More about Opko Health Inc 's Market Share
|
Emergent Biosolutions Inc
Share Performance
+19.18%
30 Days
|
Emergent Biosolutions Inc
Profile
Emergent Biosolutions Inc's business model focuses on developing and manufacturing specialty products for the prevention and treatment of public health threats.
More about Emergent Biosolutions Inc 's Market Share
|
Teva Pharmaceutical Industries Limited
Share Performance
+1.31%
This Quarter
|
Teva Pharmaceutical Industries Limited
Profile
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
More about Teva Pharmaceutical Industries Limited's Market Share
|
Viatris Inc
Share Performance
-5.37%
Over The Past 5 Days
|
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
More about Viatris Inc 's Market Share
|
Innovation1 Biotech Inc
Share Performance
0.00%
Over The Past 5 Days
|
Innovation1 Biotech Inc
Profile
The business model of Innovation1 Biotech Inc involves developing and commercializing innovative biotechnological products and solutions for various industries. The company focuses on research, development, and manufacturing, aiming to provide cutting-edge biotech solutions that meet the needs of diverse markets.
More about Innovation1 Biotech Inc 's Market Share
|
Actavia Life Sciences Inc
Share Performance
0.00%
One Year
|
Actavia Life Sciences Inc
Profile
Rasna Therapeutics Inc is a biotechnology company that focuses on developing innovative therapies for the treatment of cancer and other diseases. Their business model revolves around leveraging cutting-edge research and technology to discover and develop novel drug candidates. They aim to partner with pharmaceutical companies or license their intellectual property to bring their therapies to market and ultimately improve patient outcomes.
More about Actavia Life Sciences Inc 's Market Share
|
180 Life Sciences Corp
Share Performance
-18.08%
Over The Past 5 Days
|
180 Life Sciences Corp
Profile
180 Life Sciences Corp is a biotechnology company engaged in the research and development of novel drugs that target inflammation and fibrosis to address various diseases such as fibrosis, inflammation, and pain.
More about 180 Life Sciences Corp's Market Share
|
Allarity Therapeutics Inc
Share Performance
-7.21%
This Year
|
Allarity Therapeutics Inc
Profile
Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.
More about Allarity Therapeutics Inc 's Market Share
|
Tiziana Life Sciences Ltd
Share Performance
+9.72%
30 Days
|
Tiziana Life Sciences Ltd
Profile
Tiziana Life Sciences Ltd's business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology.
More about Tiziana Life Sciences Ltd's Market Share
|
Viracta Therapeutics Inc
Share Performance
-97.56%
One Year
|
Viracta Therapeutics Inc
Profile
Viracta Therapeutics Inc is a biopharmaceutical company focused on developing targeted therapies for viral-associated cancers. The company aims to advance research, develop innovative treatments, and commercialize products to improve the lives of patients suffering from these types of cancers.
More about Viracta Therapeutics Inc 's Market Share
|
Biophytis Sa
Share Performance
-25.59%
Over The Past 5 Days
|
Biophytis Sa
Profile
Biophytis SA is a biotechnology company that focuses on developing innovative therapeutics for age-related diseases, with a specific emphasis on degenerative eye diseases and muscle wasting conditions. They leverage their expertise in biology and clinical development to discover and advance targeted drug candidates, aiming to address the unmet medical needs of patients in these areas.
More about Biophytis Sa's Market Share
|
Hcw Biologics Inc
Share Performance
-81.15%
One Year
|
Hcw Biologics Inc
Profile
HCW Biologics Inc is a biotechnology company that operates on a business model focused on the research, development, and commercialization of biologic therapies. The company primarily focuses on developing and manufacturing novel biological products for various medical conditions. Their business model involves collaboration with industry partners, conducting clinical trials, and securing regulatory approvals for the commercialization of their biologic therapies.
More about Hcw Biologics Inc 's Market Share
|
Renovorx Inc
Share Performance
-12.50%
This Year
|
Renovorx Inc
Profile
Renovorx Inc is a medical technology company specializing in the development of innovative treatments for cardiovascular diseases. Their business model focuses on creating and commercializing minimally invasive therapies for patients suffering from conditions like myocardial infarction and heart failure. By leveraging cutting-edge medical devices and procedures, Renovorx aims to provide effective and efficient treatments that can significantly improve patient outcomes and quality of life.
More about Renovorx Inc 's Market Share
|
Indaptus Therapeutics Inc
Share Performance
-25.60%
30 Days
|
Indaptus Therapeutics Inc
Profile
Indaptus Therapeutics Inc's business model focuses on developing and commercializing innovative therapies in the healthcare industry.
More about Indaptus Therapeutics Inc 's Market Share
|
Immuron Limited
Share Performance
-16.00%
One Year
|
Immuron Limited
Profile
Immuron Limited's business model involves the development and commercialization of oral immunotherapeutics that target and treat various diseases.
More about Immuron Limited's Market Share
|
Esperion Therapeutics Inc
Share Performance
-10.33%
30 Days
|
Esperion Therapeutics Inc
Profile
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
More about Esperion Therapeutics Inc 's Market Share
|
Leap Therapeutics Inc
Share Performance
-84.68%
One Year
|
Leap Therapeutics Inc
Profile
Leap Therapeutics Inc. is a biopharmaceutical company with a business model focused on discovering and developing targeted therapies for cancer. They aim to leverage their expertise in identifying novel targets and developing antibody-based therapies to address unmet medical needs in oncology. By advancing their pipeline of innovative drugs, they seek to provide effective treatment options for patients and create value for stakeholders in the pharmaceutical industry.
More about Leap Therapeutics Inc 's Market Share
|
Cellectar Biosciences Inc
Share Performance
-91.99%
One Year
|
Cellectar Biosciences Inc
Profile
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
More about Cellectar Biosciences Inc 's Market Share
|
Xenetic Biosciences Inc
Share Performance
-24.61%
This Quarter
|
Xenetic Biosciences Inc
Profile
Xenetic Biosciences Inc is a biopharmaceutical company that focuses on developing personalized therapeutics with the potential to improve patient outcomes. The company employs a business model centered around leveraging its proprietary drug development platform to partner with pharmaceutical companies and advance novel drug candidates through preclinical and clinical stages.
More about Xenetic Biosciences Inc 's Market Share
|
Xbiotech Inc
Share Performance
-5.02%
This Quarter
|
Xbiotech Inc
Profile
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
More about Xbiotech Inc 's Market Share
|
Journey Medical Corp
Share Performance
+75.00%
This Year
|
Journey Medical Corp
Profile
Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.
More about Journey Medical Corp's Market Share
|
Mineralys Therapeutics Inc
Share Performance
+66.95%
This Quarter
|
Mineralys Therapeutics Inc
Profile
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
More about Mineralys Therapeutics Inc 's Market Share
|
Third Harmonic Bio Inc
Share Performance
+49.28%
This Quarter
|
Third Harmonic Bio Inc
Profile
Third Harmonic Bio Inc's business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.
More about Third Harmonic Bio Inc 's Market Share
|
Immunome Inc
Share Performance
-19.37%
This Year
|
Immunome Inc
Profile
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
More about Immunome Inc's Market Share
|
Mirati Therapeutics Inc
Share Performance
+22.52%
One Year
|
Mirati Therapeutics Inc
Profile
Mirati Therapeutics Inc is a biotechnology company that focuses on the research, discovery, and development of precision oncology treatments for patients with cancer. Their business model involves leveraging their proprietary drug discovery platform to identify and develop targeted therapies, and collaborating with partners for the commercialization of their products.
More about Mirati Therapeutics Inc 's Market Share
|
Prometheus Biosciences Inc
Share Performance
+3.84%
30 Days
|
Prometheus Biosciences Inc
Profile
Prometheus Biosciences Inc is a biotechnology company that operates on a subscription-based business model. Their platform offers personalized diagnostic tools and services to healthcare providers, enabling them to deliver targeted treatments for patients with gastrointestinal diseases. By providing ongoing support and monitoring, Prometheus aims to improve patient outcomes and revolutionize the management of chronic conditions in the field of gastroenterology.
More about Prometheus Biosciences Inc 's Market Share
|
Sources: Verrica Pharmaceuticals Inc and all companies mentioned above in this report
|
